Company: IMRX
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001790340-25-000053
Chunk: 42

Company: Immuneering Corp
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 42
---
ocation of a separation agreement and release with the Company and compliance with restrictive covenants contained therein, Dr. Hall will be entitled to receive, in lieu of the payments and benefits described above, (a) continued payment of Dr. Hall’s base salary for 12 months, (b) any unpaid bonus earned for the year prior to the year of termination, (c) a payment equal to 1.0 times Dr. Hall’s target annual bonus for the year of termination, (d) direct payment of or reimbursement for COBRA premiums, less the amount Dr. Hall would have paid for coverage as an active employee, for up to 12 months and (e) accelerated vesting of all equity or equity-based awards that vest solely based on Dr. Hall’s continued employment or service with the Company.

Dr. Hall is party to a restrictive covenant agreement, pursuant to which he has agreed to refrain from soliciting our customers or employees during his employment and from disclosing our proprietary information during or at any time following his employment.

#### Mr. Bookman
We entered into an employment agreement with Mr. Bookman on July 23, 2021, pursuant to which we employ Mr. Bookman as our Chief Legal Officer. The employment agreement has an indefinite term.

The employment agreement for Mr. Bookman provides for an initial annual base salary of $400,800, which was most recently increased to $502,089 effective January 1, 2025, and a target annual performance bonus equal to 40% of his base salary based on the attainment of performance objectives determined by our Board of Directors.

<div align='center'>28</div>

TABLE OF CONTENTS

In the event we terminate Mr. Bookman’s employment without “cause” or he resigns for “good reason” (as such terms are defined in the employment agreement), subject to his execution and non-revocation of a separation agreement and release with the Company and compliance with restrictive covenants contained therein, Mr. Bookman will be entitled to receive (i) his continued payment of base salary for 12 months, (ii) any unpaid bonus earned for the year prior to the year of termination, and (iii) direct payment of or reimbursement for COBRA premiums, less the amount Mr. Bookman would have paid for coverage as an active employee, for up to 12 months. If such a qualifying termination occurs on or within 12 months following the date of a change in control of the Company, subject to the execution and